anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Depression in older adults is a major public health problem and it often goes underdiagnosed and undertreated. A significant number of people with LLD, especially those with cerebrovascular risk factors, have subcortical grey matter and frontal deep white matter brain lesions. Some studies suggest that these lesions, or hyperintensities, may be associated with poor acute and long-term depression treatment response. Similarly, studies have shown that people with LLD frequently have functional deficits in the frontal lobe portion of their brains. This dysfunction has been shown to be associated with poor acute treatment response with a tricyclic antidepressant drug, as well as with a greater risk for depression relapse. The applicability of these findings to other classes of antidepressant medications, such as selective serotonin reuptake inhibitors (SSRIs), however, remains unknown. Additionally, more information is needed about the interaction between frontal brain lesions and executive function deficits in LLD. This study will determine the relationship between brain lesion severity, treatment response, and frontal lobe function in people with late-life depression who are being treated with the SSRI sertraline.

Participants in this open label study will first undergo neuropsychological testing to determine eligibility. All eligible participants will be treated with sertraline for 12 weeks. Dosages will begin at 25 mg per day, and will be increased to 50 mg per day after 4 days. Any other dosage modifications will depend on the participant's individual response to the medication. All participants will have an MRI scan at some point during the study. Assessments of symptoms and treatment response will occur at the study site biweekly until Week 8, and then again at Week 12.
Networks and methods include receiving healthcare information and with a computer identifying when a patient is readmitted to a healthcare provider. A readmission notification is generated for identified readmissions. The notification may identify the patient being readmitted, the readmitting event, prior event(s) and provider(s), substantive healthcare and clinical status for the patient, treatment dates, and/or any other desired information. Readmission alerts can be formatted and provided in accordance with their consumers' parameters. Example methods and embodiments may receive, process, store, compare, and otherwise use any of HL7 messages, CCDA information, clinical feeds, or any other type of electronic healthcare record. This information may be received from any number of different healthcare information sources and providers. With example networks and methods, readmitting providers or other consumers of readmission notifications can know exactly when a patient is readmitted and adjust the healthcare response accordingly.
Treatment of uremic pruritus is difficult due to the refractory nature of the disease, resulting in poor hemodialysis patient quality of life, pharmacological therapy is the most common clinical treatment method. Unfortunately, despite these interventions, pruritus remains a chronic problem for many dialysis patients. Recently, non-pharmacological interventions are effective for hemodialysis patients with uremic pruritus. Emollients that include Petrolatum, lanolin, mineral oil, and dimethicone were very effective, readily available, and cost-effective interventions in comparison to other methods to improve pruritus symptoms. Several studies have been conducted and show the efficiency of baby oil in controlling pruritus and enhancing sleep quality among hemodialysis patients. However these studies evaluate the short-term effect (4 weeks), Although these studies employed usual care, no-treatment group as the control condition, thus it was not possible to blind the participants. This type of control group would likely increase treatment effects from baby oil by comparison. Thus the current study will be conducted to evaluate the effect of baby oil on pruritus and sleep quality compared to a placebo control at 4 and 12 weeks followup.
Controlling access to protected information stored in a database. Certain records in the database can be designated as master records. Master records are stored in a data table. Any database record of the database may include one or more ownership data fields comprising owner identification information for identifying a master record associated with the database record. Owner identification information of the ownership data fields of a retrieved database record are analyzed to identify the master record associated with the retrieved database record. Access to the retrieved database record is controlled using the same authorization rules used to govern access to the master record associated with the retrieved database record. The system provides a mechanism to ensure that the owner identification information of any new or updated database record is linked to the correct master records. New and updated database records inherit access control from their associated master records.
PURPOSE:To obtain the titled solution useful as an antiallergic agent, etc., by dissolving glycyrrhizin or its salt in a concentrated aqueous solution of a dissolving agent such as urea, sodium benzoate, etc. at room temperature, neutrallizing the solution with a pH-adjusting agent, and diluting with water to a specific concentration. CONSTITUTION:Glycyrrhizin which is an active component of licorice, or its salt is dissolved in a concentrated solution of urea or sodium benzoate (dissolving agent of glycyrrhizin) at room temperature to obtain an acidic concentrated solution, which is adjusted to 6-7pH with a pH-adjusting agent (e.g.  alkali carbonate) and diluted with water to a specific glycyrrhizin concentration (0.1-2.0%). Since the isotonicity of glycyrrhizin solution can be attained by the use of the above dissolving agent at a proper concentration (1-3%), it is not necessary to add a particular isotonic agent. Both dissolving agents are extremely safe and have high maximum permissible doses. USE:Antiphlogistic agent, hepatic function improving agent, and gamma-interferon- inducing agent.
Inhibition of synoviolin function was found to activate the cancer-suppressing protein p53. Substances inhibiting the function of synoviolin are useful as cancer therapeutic agents. The inhibition of synoviolin function was also found to lead to the inhibition of p53 ubiquitination, increased activity of p53 phosphorylation proteins, and the like. Based on these findings, the present invention provides methods capable of efficiently screening for cancer therapeutic agents. Further, it was also found that regulation of the autoubiquitination of synoviolin protein suppresses the proliferation of rheumatoid arthritis synovial cells. Substances regulating the autoubiquitination of synoviolin protein are useful as anti-rheumatic agents. Moreover, the present invention provides methods of efficiently screening for anti-rheumatic agents.
This is a single-center, prospective, cohort study. This study will include approximate 369 post-liver transplantation patients with renal impairment and have received renal biopsy. Demographic characteristics, medical history, etiology of liver failure, concomitant medications, baseline laboratory parameters, etc., will be recorded. All participants will receive standard treatment by hepatologists and nephrologists based on the pathological results. All participants will be followed up for 96 weeks. Renal function, concomitant medications, and other laboratory parameters, etc., will be obtained.
Parasympathetic dysfunction after chronic myocardial infarction (MI) is known to predispose ventricular tachyarrhythmias (ventricular tachycardia/ventricular fibrillation [VT/VF]). VT/VF after MI is more common in males than females. The mechanisms underlying the decreased vagal tone and the associated sex difference in the occurrence of VT/VF after MI remain elusive. In this study, using optogenetic approaches, we found that responses of glutamatergic vagal afferent neurons were impaired following chronic MI in male mice, leading to reduced reflex efferent parasympathetic function. Molecular analyses of vagal ganglia demonstrated reduced glutamate levels, accompanied by decreased mitochondrial function and impaired redox status in infarcted males versus sham animals. Interestingly, infarcted females demonstrated reduced vagal sensory impairment, associated with greater vagal ganglia glutamate levels and decreased vagal mitochondrial dysfunction and oxidative stress compared with infarcted males. Treatment with 17β-estradiol mitigated this pathological remodeling and improved vagal neurotransmission in infarcted male mice. These data suggest that a decrease in efferent vagal tone following MI results from reduced glutamatergic afferent vagal signaling that may be due to impaired redox homeostasis in the vagal ganglia, which subsequently leads to pathological remodeling in a sex-dependent manner. Importantly, estrogen prevents pathological remodeling and improves parasympathetic function following MI.
Disclosed is an inhibitor of the expression of a nuclear transcription factor AP-1, which is excellent in safety and inhibitory activity on the expression of the nuclear transcription factor AP-1.  The inhibitor is characterized by comprising chamaemeloside.  Chamaemeloside may be contained in the inhibitor in the form of an extract from a plant Anthemis nobilis or Matricaia recutita.  Chamaemeloside is contained in a plant Anthemis nobilis or Matricaia recutita which has been used for a long time as a raw material for a cosmetic product or a herb tea, and therefore chamaemeloside is safe.  An extract from a plant Anthemis nobilis or Matricaia recutita or chamaemeloside can inhibit the expression of the AP-1 at a gene level (see Fig. 2), and therefore is superior in the inhibitory effect compared to a conventional inhibitor which inhibits the binding of the AP-1 to DNA.
West Virginia (WV) is in the midst of an unprecedented opioid and heroin epidemic with profound social, health, and economic consequences. This stress, especially among law enforcement officials (LEOs), is often experienced within a context of excessive anger, which decreases wellbeing and has the potential to negatively impact public wellbeing as well. These public safety personnel are often left to manage stress and anger in a cultural context that does not support help-seeking behavior and that encourages maladaptive coping mechanisms. Mindfulness-Based Resilience Training (MBRT) has demonstrated significant improvement in self-reported mindfulness, resilience, perceived operational and administrative stress, burnout, emotional intelligence, emotion regulation, mental and physical health, anger, fatigue, and sleep disturbance Introducing effective evidence-based training to first responders has the potential to improve well-being and decrease burnout and improve the performance of the people who protect the community. Should this hypotheses be confirmed, first responders in West Virginia will have an effective intervention to improve resilience, address perceived stress and burnout, and lead to greater mental and physical wellbeing in the face of unprecedented stresses associated with the opioid and heroin epidemic. This would enable this intervention to be scaled across the state among other populations of first responders in this unprecedented public health crisis.

First responders will be recruited from volunteers targeting leadership and thought leaders at the frontline from the three-county area, but primarily from the cities of Charleston and Huntington, to participate in one of two 2.5-day intensive MBRT training sessions. Each 2.5-day session will be coordinated with each agency to ensure maximum participation without disrupting work schedules. Up to 35 participants will participate in each cohort. This study aims to recruit 2 cohorts from the pool of first responders in the Cabell, Kanawha, and Putnam Counties area for a minimum of 50 participants and maximum of 70 participants. Self report measures will be conducted at time 0 (before the intervention), time 1 (after the 2.5-day intensive training), time 2 (4 weeks after the 2.5-day intensive training and after the week 4 remote/virtual booster training) and at time 3 (90 days after the initial intensive training).
Deep Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance. 20ml of 0.375% ropivacaine was slowly injected between the fascia of serratus anterior and external intercostal muscle near 5th rib.
The injection or oral administration of exogenous IL-2 can damage the original functional equilibrium in the immune system of the body itself while modulating and enhancing immune function. The four-plant compound immunoenhancers differ from the exogenous input of IL-2 preparation. The compound products can promote the formation of endogenous IL-2 in the body, regulate and enhance the immune system. It is of greater clinical significance than the supplementation of exogenous IL-2 preparation. The four-plant ingredients are absorbed, eluted, isolated and purified with WLD resin in the rigid and delicate conditions. The quantitative analysis by finger atlas with a high performance liquid chromatograph ensures the steady and uniform quality of products. The experiment on pharmacological activity shows the compound products can facilitate the formation of spleen lymphocyte IL-2 remarkably.
The invention discloses a temperature-sensitive non-steroidal anti-inflammatory drug solid dispersion and a quick-dissolving tablet and a preparation method thereof, belonging to the field of pharmaceutical dosage forms. The solid dispersion contains a non-steroidal anti-inflammatory drug and a temperature-sensitive carrier; the mass part ratio of the non-steroidal anti-inflammatory drug to the temperature-sensitive carrier is 1: (1-10). The dispersion is prepared by coprecipitating a medicament and a carrier by an anti-solvent method, separating and freeze-drying. The interaction between the non-steroidal anti-inflammatory drug and the temperature-sensitive carrier is strong, and the dispersion stability is good; after entering into the body and contacting with digestive juice, the temperature sensitive carrier generates temperature sensitive change under the hydration action to cause the phase separation of the system and release the medicine rapidly. In addition, micro-nano solid dispersion particles can be obtained through the dispersion by adjusting auxiliary materials, the fluidity and compressibility of a system are increased, and direct powder tabletting of the solid dispersion is realized. The solid dispersion can exert quick-acting effect for oral administration, and improve the relative bioavailability of the non-steroidal anti-inflammatory drug.
BACKGROUND AND PURPOSE: Research to date has lacked definitive evidence to determine whether mirror therapy promotes the recovery of upper extremity function after stroke. Considering that previous studies did not stratify patients based on structural retention, this may be one of the reasons for the negative results obtained in many trials. The goal evaluates the efficacy of TBMT (utilizing an innovatively designed mirror) versus standard occupational therapy for stroke patient's upper limb functionality.
METHODS AND ANALYSIS: This single-center randomized controlled trial will involve 50 patients with stroke. All patients will be randomly assigned to either the task-based mirror therapy or the control group. The interventions will be performed 5 days per week for 4 weeks. The primary outcomes will be the mean change in scores on both the FMA-UE and modified Barthel Index (MBI) from baseline to 4 weeks intervention and at 12 weeks follow-up between the two groups and within groups. The other outcomes will include the Action Research Arm Test (ARAT), the Nine Hole Peg Test (9HPT), the Functional Independence Measure, and MRI.
DISCUSSION: This trial will not only to establish that task-based mirror therapy (TBMT) could improve the recovery of hand function after stroke but also to explore the underlying mechanisms. We expect that this finding will clarify the brain activation and brain network mechanisms underlying the improvement of hand function with task-oriented mirror therapy and lead to new ideas for stroke hand function rehabilitation.
TRIAL REGISTRATION: URL: https://www.chictr.org.cn ; Unique identifier: ChiCTR2300068855. Registered on March 1, 2023.
The invention provides traditional Chinese medicine pills and tincture for treating premature ejaculation. A Changle essence-containing pill formula comprises 50g of amber, 60g of fossil fragments, 60g of oyster, 60g of albizia flower, 60g of saline rhizoma anemarrhence and 60g of saline cortex phellodendri, 30g of dogwood, 30g of cortex moutan, 30g of rhizoma alismatis, 30g of medlar, 30g of raspberry and 60g of rosa laevigata michx; and the medicines are ground into powder which is prepared into pills by using honey, and cinnabar is used for preparing the coats of the pills. The Changle essence-containing tincture is additionally used. A preparation method of the Changle essence-containing pill tincture comprises the following steps: soaking 100g of pericarpium zanthoxyli, 100g of asarum, 50g of fossil fragments, 50g of fructus cnidii and 50g of pippali in 1000ml of 75% alcohol for one week, filtering and bottling for later use. The two Changle essence-containing pills are taken together with light salt brine every day after supper. Little Changle essence-containing tincture is applied onto glans penis with a cotton swab three minutes before sexual intercourse every time, and then people have sexual intercourse. a treatment course lasts for 15 days, and the Changle essence-containing pill tincture is continuously used for two treatment courses. The Changle essence-containing pills and the Changle essence-containing tincture have functions of securing essence and stopping diarrhea, replenishing essence and seeding and are mainly used for treating premature ejaculation and infertility caused by premature ejaculation.
Pain science education (PSE) can be used as part of treatment and prevention for chronic pain in children. We assessed the effectiveness of PSE on knowledge, beliefs, attitudes, and behaviors in children and the people that care for children. We set a minimum criterion for education to address pain biology knowledge. We included studies aimed at both treatment and prevention of chronic pain. We conducted searches using 5 databases. We assessed the risk of bias using the Cochrane Risk of Bias 2 tool. Data were pooled using a random-effects meta-analysis or assessed using a narrative synthesis. The certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluation. We screened 14,505 records and included 7 studies involving 351 caregivers and 1,285 children. Four studies were included in meta-analyses. We found low-certainty evidence that PSE has a large beneficial effect on caregiver knowledge and beliefs compared with alternative education (standardized mean difference = 1.14 [95% confidence interval: .88-1.42]; I2 = 0%). We found no difference in functional disability in children with chronic pain after PSE (Functional Disability Inventory score mean difference = .73 [95% confidence interval: -.81 to 2.27; I = 0%]). Narrative syntheses showed low-certainty evidence for improved knowledge and beliefs in children with preventative and treatment effects. Overall, we found few studies, and along with high risk of bias, this significantly contributed to the low certainty of findings. The effect of learning pain science for both preventative and treatment effects in children, carers, and the child/carer dyad remains mostly unknown. This review was prospectively registered with The international Prospective register of systematic reviews (CRD42022344382) on July 22, 2022. PERSPECTIVE: This review examines the effect of PSE on pain-related knowledge, beliefs, attitudes, and behaviors in children and the people that care for children (0-18). The findings contribute to knowledge about pain treatments and health promotion for caregivers and their children with and without chronic pain.
The present invention provides recombinant adeno-associated virus (rAAV) vectors comprising a heterologous nucleotide sequence encoding factor VIII  (factor VIII). In preferred embodiments, the factor VIII is a B-domain deleted factor VIII. Also provided are methods of producing a high titer stock of the inventive rAAV/factor VIII vectors. Another aspect of the invention is a method of delivering a nucleotide sequence encoding factor VIII to a cell, preferably for subsequent administration to a subject. The present invention further provides methods of administering rAAV/factor VIII to a subject, e.g., for the treatment of hemophilia. The rAAV vector may be administered by any route, but is preferably administered to the liver.
Modified-constraint induced therapy (m-CIT) group will target functional goals (eg, activities of daily living) or goal subcomponents (eg, pinching, grasp/release, or functional reach patterns). Tasks were repeated at rate of approximately 10 to 50 repetitions each session according to the demands of the task. No physical constraint of the less-affected UE will be applied, but training compelled highly repetitive use of the more-affected upper extremity. Subjects will attempt tasks with progressive difficulty. Each session lasted 55-minute and it was delivered twice a week for 4 weeks (8 sessions).
OBJECTIVE: Female urethral diverticulum (UD), an evagination of the urethral mucosa into the surrounding connective tissue, is extremely rare in pregnancy. No clear guidelines on the optimal management of UD have been established, except for a common conservative approach. Here, we discuss how to manage UD with pregnancy.
CASE REPORT: A 39-year-old gravida 4, para 0, abortion 3 (G4P0A3) woman at 34+0 gestational weeks (GW) visited our outpatient department with a 6-cm septate vaginal mass. Transvaginal ultrasound sonography (TVUS) revealed a 5.5 x 4.9-cm multicystic mass, which was confirmed as UD with pelvic MRI. She was admitted because of preterm labor. A cesarean section was performed at 36+5 GW due to a previous myomectomy, and a healthy male baby was born. UD was still observed in the patient two months after delivery. Periurethral diverticulectomy was performed, and pathological analysis revealed UD with chronic inflammation and edema.
CONCLUSION: Previous reports and our case report show that UD can develop during pregnancy and that pelvic MRI is suitable for its accurate diagnosis. Vaginal delivery is possible in pregnant women with the small size of the UD. UD aspiration can permit vaginal delivery in a few cases; however, pus can occur at the aspirated site after the operation. If UD is still observed after delivery, urethral diverticulectomy is recommended.